相似文献
1
Recognizing the Early Risk-Based Clinical Manifestations of Mucormycosis: Cornerstones for Improved Survival and Therapeutic Outcomes.
J Fungi (Basel). 2025 Jul 4;11(7):507. doi: 10.3390/jof11070507.
2
Accuracy of plasma cell-free DNA PCR for non-invasive diagnosis of mucormycosis.
J Clin Microbiol. 2025 Aug 13;63(8):e0079625. doi: 10.1128/jcm.00796-25. Epub 2025 Jul 9.
3
Arora-Nagarkar Prognostic Classification for Rhinocerebral Mucormycosis: A Novel Prognostic Classification System.
Indian J Otolaryngol Head Neck Surg. 2025 Jan;77(1):412-416. doi: 10.1007/s12070-024-05210-9. Epub 2024 Nov 15.
4
One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study.
Mycopathologia. 2025 Jul 6;190(4):63. doi: 10.1007/s11046-025-00966-2.
5
Clinical Characteristics, Radiological, and Outcomes of Mucormycosis: A 14-Year Retrospective Study From Southern China.
Mycoses. 2025 Sep;68(9):e70110. doi: 10.1111/myc.70110.
6
A Global Analysis of Cases of Mucormycosis Recorded in the European Confederation of Medical Mycology / International Society for Human and Animal Mycology (ECMM / ISHAM) Zygomyco.net Registry from 2009 to 2022.
Mycopathologia. 2025 Jun 10;190(4):53. doi: 10.1007/s11046-025-00954-6.
7
Detection of antigen in bronchoalveolar lavage samples using a newly developed lateral-flow device.
J Clin Microbiol. 2025 Jun 18:e0022625. doi: 10.1128/jcm.00226-25.
8
Cutaneous mucormycosis: Unveiling rare manifestations.
J Family Med Prim Care. 2025 Jun;14(6):2561-2564. doi: 10.4103/jfmpc.jfmpc_1603_24. Epub 2025 Jun 30.
9
The burden of mucormycosis in HIV-infected patients: A systematic review.
J Infect. 2016 Sep;73(3):181-8. doi: 10.1016/j.jinf.2016.06.013. Epub 2016 Jul 7.
10
[Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary and mucormycosis].
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Jan 12;47(1):10-23. doi: 10.3760/cma.j.cn112147-20230823-00098.
本文引用的文献
1
The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis.
EClinicalMedicine. 2025 Feb 22;81:103115. doi: 10.1016/j.eclinm.2025.103115. eCollection 2025 Mar.
2
A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.
Sci Transl Med. 2025 Mar 12;17(789):eads7369. doi: 10.1126/scitranslmed.ads7369.
3
Invasive Mould Infections Following Combat-Related Injuries-A Retrospective Cohort Study.
Mycoses. 2025 Feb;68(2):e70028. doi: 10.1111/myc.70028.
4
Multiple roles for hypoxia inducible factor 1-alpha in airway epithelial cells during mucormycosis.
Nat Commun. 2024 Jun 20;15(1):5282. doi: 10.1038/s41467-024-49637-8.
5
Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs.
Open Forum Infect Dis. 2024 Jun 17;11(6):ofae257. doi: 10.1093/ofid/ofae257. eCollection 2024 Jun.
6
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
7
Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India.
Clin Microbiol Infect. 2024 Mar;30(3):368-374. doi: 10.1016/j.cmi.2023.12.006. Epub 2023 Dec 9.
8
Gastrointestinal Mucormycosis: A Clinical Review.
Gastroenterology Res. 2023 Oct;16(5):249-253. doi: 10.14740/gr1662. Epub 2023 Oct 21.
9
Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study.
Clin Infect Dis. 2024 Mar 20;78(3):775-784. doi: 10.1093/cid/ciad599.
10
Mucormycosis in 2023: an update on pathogenesis and management.
Front Cell Infect Microbiol. 2023 Sep 21;13:1254919. doi: 10.3389/fcimb.2023.1254919. eCollection 2023.
Zotero 插件